Sources: FDA prescribing information, NovoCare pricing, CMS GLP-1 Bridge FAQ, BCBSND pharmacy update, BCBS MA GLP-1 exclusion FAQ, Express Scripts 2026 formulary, GEHA plan materials, KFF Medicaid analysis, Ro published pricing · The RX Index is an independent editorial publisher covering GLP-1 medications and telehealth providers.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Wegovy Pill Insurance Coverage: What's Actually Covered in 2026
Wegovy pill insurance coverage is real in 2026 — but it is not broad, not automatic, and not the same story on every plan. If your commercial plan already covers Wegovy for weight loss, the pill will likely follow the same formulary policy — though you may still need a new prior authorization for the tablet specifically. With the Novo Nordisk savings card, eligible commercially insured patients pay as little as $25/month. If your employer plan has a weight-loss drug exclusion, the pill doesn't escape it. And if you're on Medicare, the GLP-1 Bridge starting July 2026 changes the math significantly.
No page gives you a straight answer about which of those situations applies to you. Manufacturer pages offer coverage-check tools but no decision framework. Health sites say "it depends" and point you to a phone number. We built something different: a scenario-specific breakdown of the 7 real coverage paths, what blocks each one, what each costs, and the exact next step — all verified against official insurer, PBM, CMS, and manufacturer sources this week.
If you already know your insurance doesn't cover Wegovy and want the fastest legitimate path to the pill: verified self-pay starts at $149/month for starter doses (1.5 mg and 4 mg) and $299/month at maintenance doses (9 mg and 25 mg) through NovoCare Pharmacy. No insurance needed, no PA, FDA-approved medication shipped to your door.
Wegovy pill coverage in 2026 requires understanding three things: your formulary, your plan's benefit design, and whether a PA is needed.
Your Coverage Situation at a Glance
Your situation
Likely coverage?
First step
Commercial plan already covers Wegovy / obesity meds
If your employer plan has a benefit exclusion for weight-loss drugs, Wegovy tablets are excluded too. A benefit exclusion is different from a prior authorization denial. PA denials can be appealed. Benefit exclusions generally cannot — because the benefit was never purchased.
BCBS of Massachusetts confirmed in its 2026 GLP-1 FAQ that Wegovy, Saxenda, and Zepbound are excluded from many employer plans at renewal, and that this type of exclusion cannot be appealed through the standard appeals process. On the affected BCBS MA plans, the exclusion applies to all GLP-1 indications except type 2 diabetes — meaning even the cardiovascular indication doesn't create a coverage path on those specific plans.
This saves you from the most common waste of time in GLP-1 insurance: spending two weeks chasing a prior authorization for a drug your plan was never going to cover. If your employer excluded weight-loss drugs, no amount of PA paperwork changes that. Many plans do cover the Wegovy pill — let's figure out if yours is one of them.
The real coverage scenarios for Wegovy pill in 2026. Plan design, formulary status, and prior authorization together determine your outcome.
The 7 Real Coverage Paths (April 2026)
Assembled from official manufacturer pricing, insurer formulary documents, PBM formulary lists, CMS guidance, and KFF Medicaid data. Each path is scored on a 1–5 friction scale based on formulary status, PA burden, exclusion risk, and accessibility.
Path 1: Commercial Plan Already Covers Wegovy
Friction 2/5
Easiest insurance path, but PA is standard
If your employer-sponsored or individual commercial plan already includes anti-obesity drug coverage, Wegovy tablets will typically fall under the same formulary policy as the injection. Prior authorization is nearly universal — your provider submits documentation showing you meet BMI and comorbidity criteria, and the insurer reviews it.
BCBS North Dakota published a 2026 pharmacy update confirming that Wegovy tablets were added to their commercial formulary with prior authorization. But "added to formulary" is not the same as "automatically approved" — BCBSND still requires members switching from injection to tablet to obtain a new PA.
What you'll pay: With commercial coverage plus the Novo Nordisk Savings Offer, eligible patients pay as little as $25/month (maximum savings of $100/month off your copay). Without the savings card, your copay depends on your plan's formulary tier — ranging from $25 to $299/month depending on plan design.
Your next step: Check coverage through NovoCare's online form at wegovy.com, or call the number on your insurance card and ask: "Is oral semaglutide — Wegovy tablets — on my formulary for chronic weight management?"
Path 2: Shot Was Covered, Pill Needs Its Own PA
Friction 3/5
Possible, but not automatic
You had the shot approved. You want to switch to the pill. You assume it's the same drug, same coverage, done. Not necessarily. BCBS North Dakota explicitly states that members transitioning from injectable Wegovy to oral tablets must obtain a new prior authorization, even if the injectable was already approved. The tablet is a separate National Drug Code (NDC), and many insurers treat it as a separate formulary event.
Some PBMs also haven't formally added the oral formulation yet. The pill launched in January 2026, and PBMs typically update formularies on a quarterly cycle (April, July, October). If your PBM hasn't added it, your pharmacy may get a rejection even though your injectable authorization is active.
What to do: Call your PBM or insurer and ask: (1) "Are Wegovy tablets on my current formulary?" and (2) "Do I need a new prior authorization to switch from the injection to the tablet?" If the tablet isn't on formulary yet, ask about a formulary exception.
Path 3: Covered, but Non-Preferred — Higher Cost
Friction 3/5
Coverage exists, but may not be affordable
Not all "covered" statuses are equal. GEHA's 2026 plan materials list Wegovy as non-preferred with prior authorization on several federal employee plans. Non-preferred means a higher copay tier — sometimes 40–50% coinsurance instead of a flat copay.
If Wegovy lands on a non-preferred tier and you're on a high-deductible plan, you could be paying hundreds per month until you meet your deductible. The Novo Nordisk savings card helps (up to $100 off per fill), but it can't fully offset high coinsurance on a $1,349 list-price drug.
What to do: Before assuming you're covered, ask your insurer: "What formulary tier is Wegovy tablets on, and what will my actual out-of-pocket be before and after deductible?"
Path 4: The Cardiovascular-Risk Route
Friction 3/5
Real, but narrower than most pages suggest
The Wegovy tablet is FDA-approved for two distinct indications: (1) chronic weight management in adults with obesity or overweight plus a comorbidity, and (2) reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
That second indication can matter for insurance because some plans treat "weight loss" as optional or excludable but "cardiovascular risk reduction" as medically necessary. If you have established cardiovascular disease — meaning a prior heart attack, prior stroke, or peripheral arterial disease — and you're overweight or obese, the diagnosis your prescriber codes on the PA can influence whether your plan classifies this as a covered benefit.
Important: This is not a universal workaround. Some plan-level exclusions — like the BCBS MA example — block all GLP-1 indications except type 2 diabetes. And this applies only to patients who genuinely have established cardiovascular disease. If you do have qualifying CV disease, make sure your prescriber knows — many providers default to the obesity code and miss the coverage opportunity.
If your prescriber writes Wegovy for cardiovascular risk reduction in adults with established heart disease and overweight/obesity, you go through your normal Part D plan's prior authorization process. This has been available since Wegovy received the CV indication.
This is the new, historic path — for the first time, Medicare will cover a prescription drug specifically for weight loss. The Bridge is a temporary CMS demonstration running July 1 through December 31, 2026, covering all formulations of Wegovy (injection and tablets), Zepbound KwikPen, and Foundayo.
Detail
Bridge specifics
Copay
$50/month flat
How it works
Prescriber submits PA to central Humana (LI NET) processor — not your Part D plan
Who qualifies
Part D / MA-PD beneficiaries meeting clinical eligibility (BMI + qualifying conditions)
Counts toward Part D cap?
No — Bridge copays do NOT count toward $2,100 annual out-of-pocket cap
Your insurer might be Blue Cross. Your PBM might be Express Scripts or CVS Caremark. But if your employer chose a plan design that excludes weight-loss medications, the drug being on a national formulary doesn't help you.
BCBS of Massachusetts confirmed that weight-loss GLP-1s are excluded from many employer plans in 2026. Because it's a benefit exclusion — not a utilization management decision — it cannot be appealed through normal channels.
What you can do:
1.Ask HR directly: "Does our plan include anti-obesity medication coverage?" Some employers don't realize their plan excludes it and may add the benefit at the next renewal.
2.Check whether the cardiovascular indication creates a path on your specific plan — on some exclusion designs it does, on others (like the BCBS MA example) it does not.
3.Start self-pay: Verified Wegovy pill pricing starts at $149/month for starter doses through NovoCare Pharmacy or through telehealth providers like Ro at the same manufacturer pricing.
Path 7: Medicaid / State-Program Restriction
Friction 5/5
Limited, state-dependent, and shifting
Medicaid coverage for GLP-1 weight-loss drugs remains one of the most restricted paths. According to KFF's analysis, 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026. California's Medi-Cal ended coverage for Wegovy prescribed for weight loss only as of January 1, 2026.
The BALANCE Model includes a Medicaid opt-in pathway beginning as early as May 2026 for states that choose to participate, but participation requires each state to negotiate terms individually.
What to do: Contact your state Medicaid program or check with your prescriber about current coverage. If your state doesn't cover it, self-pay starting at $149/month for starter doses is the fallback.
Fallback: Legitimate Self-Pay Pricing
If none of the seven paths work right now, the self-pay pricing is more accessible than the $1,349 list price suggests. Budget for the $299 number long-term — the starter-dose price is what you'll pay for the first couple of months during dose escalation.
Dose
Monthly Cost (NovoCare)
Notes
1.5 mg (starter)
$149/mo
Promo pricing through Aug 31, 2026
4 mg (escalation)
$149/mo → $199 after Aug 31, 2026
Price increase coming
9 mg (escalation)
$299/mo
—
25 mg (maintenance)
$299/mo
Target therapeutic dose
Sources: NovoCare Pharmacy pricing page and Wegovy.com official cost page, verified April 10, 2026.
Novo Nordisk launched a multi-month subscription program on March 31, 2026 for self-pay patients using telehealth — initially through Ro, WeightWatchers, and LifeMD — offering fixed monthly pricing with 3-, 6-, or 12-month commitments and savings of up to $600/year on the pill versus standard self-pay.
Best for: No coverage, or need help checking
Ro's free GLP-1 insurance checker tells you in minutes whether your commercial plan covers Wegovy — before you pay anything. If covered, their insurance concierge handles PA paperwork. If not, they prescribe at NovoCare's manufacturer pricing so you're not starting over somewhere else. Get started for $39, then as low as $74/month with annual plan paid upfront. Medication billed separately at manufacturer pricing.
The answer to "what does the Wegovy pill cost?" depends entirely on your insurance situation. Find your row and stop guessing.
Your Situation
Med Cost
Platform Cost
Est. Monthly Total
Commercial insurance covers Wegovy + savings card
As low as $25/mo
$0 (own doctor)
~$25
Commercial insurance covers, no savings card
$25–$299 (varies by plan)
$0 (own doctor)
$25–$299
Insurance doesn't cover — self-pay while appealing
$149–$299
$39 first mo, then $74–$149/mo (Ro)
$188–$448
Medicare GLP-1 Bridge (July–Dec 2026)
$50/mo
$0 (own doctor)
~$50
Medicare, not Bridge-eligible, self-pay
$149–$299
$39 first mo (Ro)
$188–$448
Medicaid, covered state (fee-for-service)
$0–$25
$0
$0–$25
No insurance, existing prescriber
$149–$299
$0
$149–$299
No insurance, need a prescriber
$149–$299
$39+ (Ro) or $49/visit (Walgreens)
$188–$338+
Sources: Wegovy.com official pricing, NovoCare Pharmacy, Ro.co published pricing (April 2026), CMS GLP-1 Bridge FAQ, Walgreens Weight Management. Ro membership: $39 first month, then as low as $74/month annual or $149/month monthly. Medication cost billed separately.
Important: Ro cannot coordinate coverage for most government insurance programs (Medicare, Medicaid, VA). People enrolled in Medicaid or VA are not eligible for Ro Body. Ro can coordinate FEHB (federal employee) plans.
Check Your Wegovy Pill Coverage Free
Ro's free insurance checker returns results in minutes — no payment required. If covered, Ro handles PA. If not, they prescribe at manufacturer self-pay pricing.
If Your Plan Covered the Shot, Will It Cover the Pill?
Sometimes yes. Not automatically. Here's what we know from documented insurer examples:
✓
When the answer is probably yes:
If your plan's formulary lists "Wegovy" generically (not just "Wegovy injection"), the oral formulation should fall under the same coverage policy. Both carry the same brand name, same active ingredient, same manufacturer.
!
When you still need a new PA:
BCBS North Dakota confirmed that members switching from injectable to oral Wegovy must submit a new prior authorization. The tablet has a separate NDC, and many insurers treat it as a distinct formulary event.
✗
When the answer is no (for now):
If your PBM hasn't added the oral formulation to its formulary yet, your pharmacy will get a rejection. PBMs update formularies quarterly. If you were denied in Q1 2026, check again after the April, July, or October updates.
The switching checklist:
1.Call your PBM and confirm the oral tablet NDC is on formulary
2.Ask whether your existing injectable PA transfers or if you need a new one
3.If a new PA is required, have your doctor submit it with your reason for switching (convenience, travel, preference, needle avoidance)
4.If the tablet isn't on formulary, request a formulary exception citing clinical need for the oral form
5.Keep your injectable authorization active until the tablet PA is confirmed — don't create a gap in treatment
Prior authorization for the Wegovy pill isn't a mystery. Insurers check a small number of specific things, and knowing them in advance cuts weeks off the process.
The four checks every insurer runs for Wegovy pill prior authorization. The fastest path: verify coverage, get the PA criteria, send it to your prescriber.
1. Is the tablet on formulary?
If not, you need a formulary exception before anything else moves forward.
2. Does your plan include anti-obesity drug coverage?
This is the gate most people don't know exists. Even if Wegovy is on the national formulary for your PBM, your specific employer may have purchased a plan that excludes weight-loss drugs. If so, PA is irrelevant.
3. BMI and comorbidity criteria
Virtually every plan requires BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Your doctor documents this.
4. Lifestyle modification evidence
Most insurers want documentation that you've attempted diet and exercise modification — sometimes for 3–6 months. This can be as simple as chart notes from your provider showing you discussed nutrition and activity.
5. Covered diagnosis and diagnostic coding
Whether the prescription is coded for weight management (ICD-10: E66.01, E66.09) versus cardiovascular risk reduction can influence how your plan classifies the claim.
6. Quantity limits and refill timing
Wegovy tablets are dispensed as a 30-day supply (vs 28-day supply for injection pens). Some plans impose quantity limits during initial dose escalation months.
5 Questions to Ask Your Insurer Before You Spend a Dollar
1."Are Wegovy oral semaglutide tablets on my current formulary, and what tier?" — This tells you whether coverage exists and your copay structure.
2."Does my employer plan include anti-obesity medication coverage, or is there a weight-loss drug exclusion?" — This is the question that saves you two weeks.
3."What are the exact prior authorization criteria for Wegovy tablets?" — Ask for the criteria document, not a summary. Your doctor needs the specific requirements.
4."Is coverage under my pharmacy benefit or my medical benefit?" — Affects where you fill and how cost-sharing works.
5."What will my actual out-of-pocket cost be before and after deductible, with and without the Wegovy savings offer?" — The only number that matters for your budget.
Print those five questions. Call with them in hand. You'll get more useful information in 10 minutes than most people get in a month of searching.
How to Check Wegovy Pill Coverage Without Wasting Weeks
The standard advice — "call your insurance" — is technically correct and practically useless. Here's the workflow that gets you a real answer fast.
1
Check coverage digitally first (5 minutes)
Go to NovoCare's online coverage form at wegovy.com. Enter your insurance information. Most results come back in minutes. Alternative: Ro's GLP-1 insurance checker is free and returns results without requiring payment or commitment.
2
Call your insurer with the 5-question script above (15 minutes)
Write down the answers. Get the name and reference number of the person you spoke with. If they say the tablet isn't on formulary, ask when formulary updates happen and whether a formulary exception is possible.
3
Request the full PA criteria document (1 minute)
Ask the insurer to send or email you the prior authorization criteria for Wegovy tablets. Your doctor needs this exact document to submit the PA correctly the first time. An incomplete submission is the top cause of avoidable delays.
4
Send the criteria to your prescriber (5 minutes)
Forward the PA criteria to your doctor's office. If your doctor seems unfamiliar with GLP-1 prior authorizations, that's a signal to consider a telehealth provider that handles PAs routinely — Ro, for example, has submitted thousands.
5
Decide — pursue insurance or start self-pay (your call)
If the PA looks straightforward and your coverage is confirmed, wait for approval (typically 1–3 weeks). If it looks like a long shot, consider starting self-pay now. You don't lose anything by beginning treatment while the paperwork processes. Many people do both simultaneously.
Free Ro coverage check — no payment required
If covered, Ro's concierge handles PA. If not, they prescribe at manufacturer self-pay pricing.
KFF's analysis shows 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026. Managed care organizations in some states may have different policies. California's Medi-Cal dropped Wegovy coverage for weight loss only as of January 1, 2026. The BALANCE Model Medicaid opt-in begins as early as May 2026, but each state must join individually.
BCBS: Moving in Different Directions
✓
BCBS North Dakota
Added Wegovy tablets to its commercial formulary with PA requirements.
✗
BCBS of Massachusetts
Excluded Wegovy and other weight-loss GLP-1s from many employer plans at renewal, covering only the type 2 diabetes indication on affected plans.
Blue Cross Blue Shield isn't one insurer — it's a federation of independent affiliates. If you have BCBS, your affiliate matters more than the national brand. Call your specific plan.
PBMs: Formulary Position ≠ Your Employer's Decision
Express Scripts' 2026 National Preferred Formulary lists Wegovy injection and Wegovy tablets as preferred alternatives — the PBM's default is to include them, not exclude them. But an employer using Express Scripts can still customize their plan to exclude anti-obesity drugs.
CVS Caremark issued a February 2026 policy update adding Wegovy oral tablets and has continued to position Wegovy as preferred over Zepbound in its formulary communications. The takeaway: if your PBM's national formulary includes Wegovy tablets, that's a positive signal — but you still need to confirm your specific employer plan bought the anti-obesity benefit.
Best Next Step Based on Your Situation
"I have commercial insurance and want help checking if the pill is covered"
Best path: Ro. Ro's free GLP-1 insurance checker returns coverage results in minutes. If you're covered, their insurance concierge handles prior authorization. With the Wegovy savings card stacked on insurance, your medication could cost $25/month. If coverage is denied, Ro prescribes the Wegovy pill at NovoCare's manufacturer pricing ($149/month starter, $299/month maintenance) without requiring you to start over elsewhere.
Ro charges a separate membership: $39 for the first month, then as low as $74/month with annual plan paid upfront, or $149/month paid monthly. Medication is billed separately at manufacturer pricing.
Free coverage check · PA concierge included with membership · Get started for $39
"I already have a prescription and just want the cheapest self-pay"
Best path: NovoCare Pharmacy direct. If you already have a prescriber, NovoCare Pharmacy ships FDA-approved Wegovy directly to you at $149/month (starter) or $299/month (maintenance). No platform fee. No membership. Your prescriber submits an electronic prescription to NovoCare Pharmacy through their EHR/EMR.
"My plan excludes obesity drugs"
1.Check whether the cardiovascular indication creates a path on your specific plan — it does on some plans.
2.Ask HR about adding the benefit at the next renewal.
3.Self-pay at $149/month starter through Ro or NovoCare while you work the coverage angle.
"I'm on Medicare"
If you have established cardiovascular disease and overweight/obesity, check with your Part D plan about standard coverage under the CV indication — that path exists now. If you'll qualify for the GLP-1 Bridge in July, that's $50/month for weight loss. If neither works today and you want to start now, self-pay through Ro is an option — but Ro cannot coordinate Medicare coverage.
Check your state Medicaid program for current coverage rules. Ro is not available to people enrolled in Medicaid or VA programs.
Can I Use the Wegovy Savings Card for the Pill?
Detail
How it works
Eligibility
Certain commercially insured patients, certain uninsured patients. Government insurance (Medicare, Medicaid, TRICARE) excluded.
Savings
As little as $25/month — maximum savings of $100 per fill
How to enroll
Text SAVE to 83757 or visit novocare.com for the digital savings offer
Pill-specific detail
A 30-day supply of Wegovy pill = one month of treatment (injection pen is a 28-day supply)
Stacking
Cannot combine with GoodRx — use whichever gives the lower price for a given fill
One nuance: The $100/month maximum savings works best when your copay falls in the $50–$125 range. If your copay is already $25, the card isn't adding much. If your copay is $300+ because you're on a high-deductible plan pre-deductible, the card brings it down $100 — helpful, but you're still paying $200+.
Is the Wegovy Pill Covered for Heart Disease?
The Wegovy tablet is FDA-approved to reduce the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with established cardiovascular disease who are either obese or overweight.
1. "Established cardiovascular disease" is a specific clinical definition
Prior heart attack, prior stroke, or peripheral arterial disease. Not high blood pressure or high cholesterol alone.
2. The diagnosis code matters
The ICD-10 codes for the cardiovascular indication differ from the obesity codes. How the prescription is coded can influence the coverage decision on plans where the distinction matters.
3. This doesn't work everywhere
On plans like the affected BCBS MA designs that exclude all GLP-1 indications except diabetes, the CV route is blocked. Check your specific plan's exclusion language.
Is the Wegovy Pill the Same as Compounded Semaglutide?
FDA-approved Wegovy tablets and compounded semaglutide are not the same product — they differ in regulatory status, manufacturing standards, and clinical evidence.
No. NovoCare explicitly states that Wegovy tablets 25 mg are FDA-approved and compounded semaglutide is not.
The FDA resolved the semaglutide shortage in February 2025, which ended the legal basis for most compounded semaglutide production. Compounded oral semaglutide products you might see online are not the same as the Wegovy pill — they haven't gone through the same FDA review process, may have different bioavailability, and don't carry the same clinical trial evidence.
If someone is offering you "oral semaglutide" at a price significantly below Novo Nordisk's official pricing, verify exactly what you're getting. The FDA-approved Wegovy tablet is manufactured by Novo Nordisk and dispensed through licensed pharmacies.
What Real Users Say About the Process
From public Reddit communities — individual user reports, not guaranteed outcomes.
"Using the Ro website I was successfully prescribed the Wegovy pill… The online process [has] been smooth…"
— r/RoBody user, 2026
"They've done two PAs for me with no issues."
— r/RoBody user discussing Ro's prior authorization handling
"They responded instantly and had medication to my pharmacy within 10 minutes."
— r/RoBody user on prescribing turnaround
"I checked NovoCare that my insurance… will pay for Wegovy pills if given prior authorization ($30 for a 30 day supply…)"
— r/RoBody user who checked coverage first
The pattern is consistent: the people who checked coverage first, understood their PA requirements, and had a platform handling the paperwork had the smoothest experience. Know your path before you commit.
Ready to find out if your plan covers the pill?
Free check. No payment required. Insurance concierge included if you move forward.
Wegovy tablet addition, preferred status over Zepbound
February 2026
How friction scores were assigned: Each path scored 1–5 on four factors: (1) whether the drug is on formulary by default or needs an exception, (2) PA complexity, (3) risk of a benefit exclusion blocking coverage entirely, (4) how broadly accessible the path is versus being restricted to a narrow population.
What we could not independently verify: We could not verify the internal formulary status of every commercial insurer in every state. The examples we cite (BCBSND, BCBS MA, GEHA, Express Scripts, CVS Caremark) are documented public examples. Your specific plan may differ.
On some commercial plans, yes. Coverage exists for plans that include anti-obesity medications, and the Novo Nordisk savings offer can reduce the copay to as little as $25/month for eligible patients. However, many employer plans exclude weight-loss drugs entirely, and coverage is not standardized across insurers. Medicare's GLP-1 Bridge starts covering Wegovy tablets for weight loss in July 2026.
Does Medicare cover the Wegovy pill?
Medicare Part D can cover Wegovy when prescribed for cardiovascular risk reduction in adults with established heart disease and overweight/obesity — that path exists now through your normal Part D plan. Starting July 1, 2026, the Medicare GLP-1 Bridge covers all Wegovy formulations (including tablets) at $50/month for weight loss in eligible beneficiaries. The Bridge runs through December 31, 2026.
Does Medicaid cover the Wegovy pill?
Coverage is limited and state-specific. KFF reports 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026. The BALANCE Model Medicaid opt-in begins as early as May 2026 for participating states, but each state joins individually.
If my shot was covered, will the pill be covered too?
Not automatically. BCBS North Dakota confirmed that switching from injectable to oral Wegovy requires a new prior authorization, even with an existing injectable approval. Some PBMs haven't added the oral formulation to their formularies yet. Check with your PBM before assuming your injectable coverage transfers.
What does the Wegovy pill cost with insurance?
Eligible commercially insured patients with coverage may pay as little as $25/month with the Novo Nordisk savings offer (maximum savings $100/month). Without the savings offer, copays range from $25 to $299/month depending on your plan's formulary tier, deductible status, and cost-sharing design.
What does the Wegovy pill cost without insurance?
Verified self-pay prices through NovoCare Pharmacy: $149/month for 1.5 mg and 4 mg tablets (starter doses), $299/month for 9 mg and 25 mg tablets (maintenance doses). The 4 mg promotional pricing of $149/month increases to $199/month after August 31, 2026.
Can I use the Wegovy savings card with Medicare or Medicaid?
No. The Novo Nordisk Savings Offer is not available to government insurance beneficiaries — including Medicare, Medicaid, and TRICARE. Medicare beneficiaries can access the GLP-1 Bridge ($50/month) starting July 2026 for weight loss, or standard Part D coverage for the cardiovascular indication.
Is oral Wegovy covered for heart disease?
Wegovy tablets are FDA-approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. On some insurance plans, that cardiovascular indication can create a coverage path when the weight-management indication is excluded — but this is plan-specific and not universal.
Is the Wegovy pill the same thing as compounded semaglutide tablets?
No. NovoCare explicitly states that Wegovy tablets 25 mg are FDA-approved and compounded semaglutide is not. They are different products with different regulatory status, manufacturing standards, and clinical evidence.
Still not sure which GLP-1 program is right for you?
5 questions · Free · No email required · Personalized recommendation based on your insurance, budget, and medical situation.
